Małopłytkowość immunologiczna: badanie fazy II leku diphenhydramine hydrochloride
Safety and Efficacy Study of PF-06835375 in Primary Immune Thrombocytopenia
Badania kliniczne, które rekrutują lub wkrótce zaczną rekrutację w ośrodkach w mieście Białystok. Najwięcej badań dotyczy: cukrzyca, otyłość, rak płuca, rak jajnika.
309 badań: 294 rekrutują, 15 wkrótce zacznie.
Safety and Efficacy Study of PF-06835375 in Primary Immune Thrombocytopenia
A Study to Evaluate the Safety and Tolerability of Dapirolizumab Pegol in Study Participants With Systemic Lupus Erythematosus
Selatogrel Outcome Study in Suspected Acute Myocardial Infarction
European Disease Registry on Retinopathy of Prematurity (ROP)
Obinutuzumab Versus Rituximab for Acute Lymphoblastic Leukemia/PALG ALL7 "OVERALL"
Nivolumab in Nasopharyngeal Cancer With Progression During or After Platinum-based Treatment
A Study to See if Tolvaptan is Safe in Infants and Children Who at Enrollment Are 28 Days to Less Than 18 Years Old With Autosomal Recessive Polycystic Kidney Disease (ARPKD)
Dual Antithrombotic Therapy With Dabigatran and Ticagrelor in Patients With ACS and Non-valvular AF Undergoing PCI
Polish Registry of Diabetes (PolReD)
Secukinumab Open Label Roll-over Extension Protocol
The Bialystok Bariatric Surgery Study
Clinical Value and Cost-effectiveness of a Personalized Prevention Program (PPP) in Patients With High Risk Stable CHD
Roll Over StudY for Patients Who Have Completed a Previous Oncology Study With Olaparib
Trifecta-Kidney cfDNA-MMDx Study
International Cooperative Treatment Protocol for Children and Adolescents With Lymphoblastic Lymphoma
An open-label study to assess safety and efficacy of SZC in paediatric patients with hyperkalaemia
A Study Evaluating the Long-Term Efficacy and Safety of Ralinepag in Subjects With PAH Via an Open-Label Extension
A Study to Evaluate the Safety (Compared to Iron Sucrose), Efficacy and Pharmacokinetics of Ferumoxytol for the Treatment of Iron Deficiency Anemia (IDA) in Pediatric Subjects…
A Multicenter, Open-label, Phase 3 Study to Evaluate the Long-term Safety and Efficacy in Participants who are Currently on Treatment or in Follow-up in Studies That Include…
Białystok PLUS - Polish Longitudinal University Study
Paediatric Hepatic International Tumour Trial
EuroSIDA - Clinical and Virological Outcome of European Patients Infected With HIV
High Risk Neuroblastoma Study 1.8 of SIOP-Europe (SIOPEN)
Global Patient Registry to Monitor Long-term Safety and Effectiveness of Increlex® in Children and Adolescents With Severe Primary Insulin-like Growth Factor-1 Deficiency (SPIGFD).
A prospective, randomized, double-blind, placebo-controlled, multicenter clinical trial to evaluate the efficacy and safety of subcutaneous immunotherapy with polymerized grass…
A Phase 3, Double-Blind, Placebo-Controlled Study to Investigate the Efficacy and Safety of Olatorepatide, a GLP-1/GIP Receptor Agonist, in Participants Living with Overweight or…
Study to Learn About a Respiratory Syncytial Virus Vaccine in Children at High Risk of RSV Disease
A Phase 3, Randomized, Double-Blind Extension Trial to Evaluate the Long-term Efficacy, Safety, and Tolerability of Maridebart Cafraglutide in Participants with Obesity or…
Zenagamtide use for the reduction of risk of major adverse cardiovascular events in people with established atherosclerotic cardiovascular disease and either overweight or…
A phase III, randomized, prospective, double-blind, parallel design, multi-arm, multicenter study to compare the efficacy and safety of alogliptin and empagliflozin combination…
Zadzwoń i porozmawiaj z doradcą ds. badań klinicznych. Sprawdzimy w rejestrach, do których badań możesz się kwalifikować.
Nie udzielamy porad ani konsultacji medycznych. Pomagamy znaleźć badanie i skontaktować się z ośrodkiem.
Informacje pochodzą z publicznych rejestrów badań klinicznych (CTIS - Unia Europejska, ClinicalTrials.gov - USA) i są aktualizowane codziennie. Mogą różnić się od aktualnego stanu w ośrodku. Ostateczną kwalifikację do badania zawsze przeprowadza lekarz w ośrodku badawczym. Stan na 3 października 2026.